China imposes remedies on below-threshold deal for first time
Simcere Pharmaceutical Group has won conditional approval for its acquisition of Beijing Tobishi Pharmaceutical, marking the first time China’s competition authority has remedied a deal that fell below merger notification thresholds.
To read more
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.